JID VisualDx Quiz
JID VisualDx Quiz: January 2015 Arsalan Shabbir1 and Robert S. Kirsner1 Journal of Investigative Dermatology (2015) 135, e24. doi:10.1038/jid.2014.473
JID and Logical Images, Inc., have cooperated to offer the JID VisualDx Quiz, incorporating diagnostic images from VisualDx’s vast database. Questions relate to the image as well as to selected articles in JID, which are listed after the questions. Answers will be posted as supplementary material. We hope you enjoy this challenge.
Image appears with permission from VisualDx. © Logical Images, Inc.
QUESTIONS 1. What is your diagnosis? a. Bullous pemphigoid. b. Urticaria. c. Subacute cutaneous lupus. d. Erythema multiforme. e. Urticaria pigmentosa.
Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA
1
© 2015 The Society for Investigative Dermatology
www.jidonline.org
1
JID VisualDx Quiz
2. How does the ASTERIA I study differ from previous studies of omalizumab for chronic idiopathic urticaria? a. Dosing of the drug. b. Inclusion criteria. c. Duration of the study. d. Ability to use additional concurrent drugs. e. All of the above. 3. From the results of this study, which of the following is true regarding omalizumab for chronic idiopathic urticaria (CIU) (choose all that apply)? a. Improves CIU in a dose-dependent fashion. b. Most clinical improvement is experienced soon after initiation. c. Maximal benefit was demonstrated with this study. d. Placebo effect is most persistent of all treatments. e. All of the above.
TOPIC ARTICLE Questions 2 and 3 refer to the following article: Saini SS, Bindslev-Jensen C, Maurer M et al. (2015) Efficacy and safety of omalizumab in patients with chronic idiopathic/ spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 135:67–75
Answers are available as supplementary material at http://dx.doi.org/10.1038/jid.2014.473.
2
Journal of Investigative Dermatology (2015), Volume 135
Copyright of Journal of Investigative Dermatology is the property of Nature Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.
JID VisualDx Quiz: January 2015 Arsalan Shabbir1 and Robert S. Kirsner1 Journal of Investigative Dermatology (2015) 135, e24. doi:10.1038/jid.2014.473
JID and Logical Images, Inc., have cooperated to offer the JID VisualDx Quiz, incorporating diagnostic images from VisualDx’s vast database. Questions relate to the image as well as to selected articles in JID, which are listed after the questions. Answers will be posted as supplementary material. We hope you enjoy this challenge.
Image appears with permission from VisualDx. © Logical Images, Inc.
QUESTIONS 1. What is your diagnosis? a. Bullous pemphigoid. b. Urticaria. c. Subacute cutaneous lupus. d. Erythema multiforme. e. Urticaria pigmentosa.
Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA
1
© 2015 The Society for Investigative Dermatology
www.jidonline.org
1
JID VisualDx Quiz
2. How does the ASTERIA I study differ from previous studies of omalizumab for chronic idiopathic urticaria? a. Dosing of the drug. b. Inclusion criteria. c. Duration of the study. d. Ability to use additional concurrent drugs. e. All of the above. 3. From the results of this study, which of the following is true regarding omalizumab for chronic idiopathic urticaria (CIU) (choose all that apply)? a. Improves CIU in a dose-dependent fashion. b. Most clinical improvement is experienced soon after initiation. c. Maximal benefit was demonstrated with this study. d. Placebo effect is most persistent of all treatments. e. All of the above.
TOPIC ARTICLE Questions 2 and 3 refer to the following article: Saini SS, Bindslev-Jensen C, Maurer M et al. (2015) Efficacy and safety of omalizumab in patients with chronic idiopathic/ spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 135:67–75
Answers are available as supplementary material at http://dx.doi.org/10.1038/jid.2014.473.
2
Journal of Investigative Dermatology (2015), Volume 135
Copyright of Journal of Investigative Dermatology is the property of Nature Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.
